SmarTrend is bearish on shares of ILMN and our subscribers received a Downtrend alert on October 28, 2009 at $34.34, which has returned 15.3% to date.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Deal Type    Partnership
Sub-Category Licensing Agreement
Deal Status  Announced: 2009-11-18

Deal Participants

Partner 1 (Company) Illumina, Inc.
Partner 2 (Company) EraGen Biosciences, Inc.

Deal Rationale

This alliance is part of EraGen's strategy to continue to expand its commercial efforts in the molecular diagnostics market.

"We are very excited by the opportunities this partnership presents to EraGen. Our newly formed relationship with Illumina further validates our MultiCode technology's versatile application in the development and commercialization of molecular-based assays for the clinical market," stated Irene Hrusovsky, M.D., President and CEO of EraGen Biosciences Inc.

"We look forward to seeing the delivery of innovative solutions through the combination of Illumina and EraGen technologies," said Greg Heath, Senior Vice President and GM of Illumina's diagnostic division. "We view this agreement as a first step toward advancing healthcare through leading-edge molecular tools."

This partnership is part of EraGen's strategy to continue to expand its commercial efforts in the molecular diagnostics market.

"We will continue to bring to market innovative, high-value molecular diagnostic tests and solutions through strategic platform partnerships and the advancement of a broad product pipeline that is responsive to our customers' needs," added Dr. Hrusovsky.

EraGen's goal is to provide its customers in the molecular diagnostics laboratory with an integrated solution that provides rapid, reliable results for improving the clinical management of patients.

About EraGen Biosciences

EraGen Biosciences develops, manufactures and markets molecular reagent products that are driving a new era in clinical diagnostics. The company's in-market and pipeline products, based on its novel, patented MultiCode(R) platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic-based conditions. EraGen's expanding menu of high quality, easy-to-use products position the company for leadership in the molecular diagnostics market. For more information, visit the EraGen website at www.eragen.com.

SOURCE: EraGen Biosciences Inc.

Linda Pauls 
Chief Financial Officer, EraGen Inc. 
608-662-9000 
Rod Hise 
The Luminis Group, Ltd. for EraGen Inc. 
608-770-7850

Want access to these reports and real time alerts? Go to www.tradethetrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html